Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 205082, held by Actavis Mid Atlantic. Desoximetasone.
As of Nov 15, 2026, ANDA 205082 (Desoximetasone), held by Actavis Mid Atlantic, was first approved by FDA on Sep 4, 2015, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Desoximetasone cream USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 4, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · cream;topical | Desoximetasone | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
